Company Overview
Phibro Animal Health Corporation is an American company specializing in animal nutrition and health solutions. Based in Teaneck, New Jersey, Phibro is dedicated to supporting farmers in managing livestock with products like antibacterials, anticoccidials, and anthelmintics. The company focuses on enhancing the health and productivity of animals such as beef cattle, dairy cows, poultry, and swine. Phibro's headquarters is located in Teaneck, New Jersey, with an employee base between 1,001 and 5,000, categorizing it among mid-sized entities within the pharmaceutical manufacturing industry. Notably, Phibro recently acquired Zoetis' medicated feed additive (MFA) product portfolio for $350 million. Additional details can be found on their [official website](https://www.pahc.com/).
Key Executives
- Jack C. Bendheim: Chairman of the Board, President, and Chief Executive Officer. Serving as CEO since March 2014, President since 1988, and director since 1984. His total yearly compensation amounts to $4.75 million, with 49.6% as salary. He has been pivotal in the company's strategic growth and acquisitions.
- Larry L. Miller: Chief Operating Officer. Joined Phibro as President of Animal Health in May 2008 and assumed the role of COO in July 2016. Miller brings over three decades of leadership experience.
- Glenn David: Chief Financial Officer since February 2024. David has over 30 years of financial and commercial leadership expertise from previous roles at Zoetis and Pfizer.
- Daniel M. Bendheim: Director and Executive Vice President, Corporate Strategy, has been with Phibro since 1997. He oversees corporate strategy and long-term growth planning.
- Rob Aukerman: President, North America Region, who joined in May 2019, offers extensive expertise in management within the animal health industry.
- Jonathan Bendheim: Director, President, MACIE Region, General Manager, Israel Operations. He has been in various leadership roles at Phibro since 2004.
- Samson Li: President, Asia Pacific Region. Li was appointed in April 2023 with significant global expertise in the animal health industry.
- Ramon Fuenmayor: President, South America Region, who joined in June 2017, previously a Managing Partner with a proven industry track record.
- Michael Giambalvo: President, PhibroChem and Ethanol Performance Group, having joined in 2002, has driven growth in specialty chemicals.
Strategic Movement
Phibro Animal Health is actively pursuing strategic acquisitions and expansions to bolster its industry standing. The recent acquisition of Zoetis' product portfolio is set to substantially augment its offerings.
For ongoing updates and contact details, Phibro suggests visiting their [Investor Relations page](https://investors.pahc.com/home/default.aspx).
Competitive Landscape
Phibro operates in a competitive animal health sector, directly competing with major industry players who regularly advance in technology and market presence.
Key Competitors
1. Zoetis Inc
- Overview: A leading global animal health company, Zoetis excels in medicines, vaccines, and diagnostics, with operations across more than 100 countries.
- Financials: Reported $9.3 billion in revenue in 2024; employs approximately 13,800 people, headquartered in Parsippany, NJ, USA.
- Highlights: Strong financial performance with a recent USDA license for an Avian Influenza Vaccine.
- Strategic Initiatives: Focused on sustainability and AI enhancements in veterinary services, alongside a $1.2 million initiative for pastoralist communities in Kenya and Ethiopia.
2. Huvepharma
- Overview: A burgeoning pharmaceutical entity emphasizing fermentation and quality animal health products, distributed in over 90 countries.
- Headquarters: Located in Sofia, Bulgaria; significant manufacturing through its subsidiary Biovet.
- Direction: Pursues organic growth and strategic acquisitions with a customer-focused approach.
3. Ceva Santé Animale
- Overview: The world's fifth-largest animal health company with innovative solutions for poultry, swine, and companion animals.
- Headquarters: Based in Libourne, France, Ceva supports R&D and maintains several production sites.
- Strengths: Leadership in poultry vaccination and preventive medicine.
4. Boehringer Ingelheim
- Overview: Offers a comprehensive array of animal health products. A private entity operating from Germany with substantial annual revenues around $27.7 billion.
- Focus: Stresses innovation in animal health, providing competitive pressure in the marketplace.
5. Alltech
- Overview: Specializes in integrating nutrition and scientific innovation to advance efficiency in agriculture, active in over 140 countries.
- Financials: Reports a revenue of $3.2 billion with a global workforce exceeding 5,000.
- Mission: Driven by the ACE principle, focusing on the health of animals, consumers, and the environment.
6. Proteon Pharmaceuticals
- Overview: An innovative biotechnology firm advancing in bacteriophage platforms, particularly for aquaculture and livestock.
- Headquarters: Located in Lodz, Poland, known for sustainable solutions to reduce antibiotics in animal health.
Phibro Animal Health's competitive landscape is characterized by its rivals' constant technological advancements and expanding market reach, demanding Phibro's focus on innovation and strategic growth to sustain its positioning.
